Warde Medical Laboratory

LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Molecular

Collected: 08/25/2023 11:58 Received: 08/25/2023 11:58

Test Name	Result	Flag	Ref-Ranges	Units	Site
BCR-ABL1 Major (p210) Rearrangement, Quantitative PCR					
p210 Result	Not detected		see below		WMRL
p210 %IS	N/A		see below	%	WMRL
p210 MR	N/A		see below		WMRL
BCR-ABL1 Major (p210) Comment	see below		see below		WMRL

The e13a2, e14a2 for the p210 product were not detected. This test does not monitor other rare fusion transcripts resulting from t(9;22). This test is not intended for the diagnosis of CML.

This test was performed using the QuantideX® qPCR BCR-ABL IS Kit (Assuragen). The QuantideX® qPCR BCR-ABL IS kit is an in vitro nucleic acid amplification test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcripts type e13a2 and/or e14a2. The QuantideX® qPCR BCR-ABL IS Kit is a reverse transcription-quantitative PCR performed on the Applied Biosystems 7500 Fast Dx Real-Time OCR Instrument and is intended to measure BCR-ABL1 to ABL1, expressed as a log molecular reduction (MR value) from a baseline of 100% on the International Scale, in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).

Performing Site:
WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

Reported Date: 2023.08.25 11:58 BCRMJ

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F225000009
WX0000003827
Printed D&T: 08/25/23 11:59

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1